Immunology
Solid organ transplantation
Viral infections
Multi-Drug Resistant Bacteria
Oncology
Others
Odile
Duvaux
Bernard
Vanhove
Chief Scientific Officer
Ph. D., immunologist, Research Director at CNRS and INSERM, co-founder and ex-COO of Effimune and Ose Immuno
Françoise
Shneiker
A clinical stage Biotech
XENOTHERA is a clinical stage biotech at the top of innovation, which creates new therapeutic modes in numerous domains. Our patented technological platform is built on a double expertise of immunology and genetic engineering. We develop innovative approaches in immunotherapy by marketing Glyco-Humanized Polyclonal Antibodies (GH-pAb). Our antibodies are engineered to display high therapeutic properties. XENOTHERA’s platform ensures short-time development thanks to our mastery of the entire process, from animal genetics, choice of the immunogen, selection and purification of antibodies, and access to market authorization in accelerated timescale. Within less than 8 years, XENOTHERA has brought to clinic LIS1, a novel induction treatment in Solid Organ Transplantation, addressing a $1Bn market. and XAV19, its anti-COVID treatment for patients with moderate disease. It has also established in vivo Proof-of-Concept in Immuno-Oncology and Multi-Drug Resistant infections.
XAB05 CTA
Serie B
Phase II
Phase II/IIIPhase I/II
XAB05 & XON POC in vivoPreclinical package
Series ASeed funding
LIS1
Proof of concept
Company creation
Pipeline
Products in development

Latest
News
[Newsletter] XENONEWS
February 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...
More[Press Alert] Omicron Variant : positive results for XENOTHERA's XAV-19 antibody
# Download our press information (english version) # Télécharger notre communiqué de...
More[Press information] XENOTHERA announces the continuation of development of its anti-SARS-CoV-2 antibody.
January 2022. # Download our press information (english version) # Télécharger notre...
MoreRelated
scientific papers
XENOTHERA is a start-up in biotechnology, specialized in immunology, transplantation,
infectious diseases and oncology.
Investors already trusted us since creation by funding the company more than 30M€,
completed with 15M€ non-dilutive financing. Our products will offer a substantial patient benefit
and address unsolved major public health issues
To contact us, use the form or see our full contact below:
XENOTHERA
1 rue Vauban – 44000 Nantes – France
To work with us: careers@xenothera.com
Press Contact: IZsoGOOD – Ingrid Zémor – xenothera@izsogood.co